Genmab A/S Sponsored ADR (NASDAQ:GMAB – Free Report) – Investment analysts at HC Wainwright lifted their Q3 2026 earnings per share (EPS) estimates for Genmab A/S in a research report issued on Monday, October 19th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings per share of $0.49 for the quarter, up from their prior forecast of $0.48. HC Wainwright currently has a “Buy” rating and a $50.00 price target on the stock. The consensus estimate for Genmab A/S’s current full-year earnings is $1.20 per share. HC Wainwright also issued estimates for Genmab A/S’s Q4 2026 earnings at $0.46 EPS, FY2026 earnings at $1.51 EPS, Q1 2027 earnings at $0.35 EPS, Q2 2027 earnings at $0.59 EPS, Q3 2027 earnings at $0.60 EPS and FY2027 earnings at $2.15 EPS.
A number of other equities research analysts also recently issued reports on the stock. Weiss Ratings upgraded shares of Genmab A/S from a “hold (c)” rating to a “hold (c+)” rating in a report on Tuesday, September 1st. Morgan Stanley set a $42.00 price target on shares of Genmab A/S in a research note on Tuesday. New Street Research set a $43.00 price target on shares of Genmab A/S in a research note on Wednesday, July 22nd. Truist Financial lifted their price target on shares of Genmab A/S from $40.00 to $45.00 and gave the company a “buy” rating in a report on Wednesday, October 7th. Finally, Guggenheim boosted their price objective on shares of Genmab A/S from $45.00 to $54.00 and gave the company a “buy” rating in a research note on Monday, October 5th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Genmab A/S presently has a consensus rating of “Moderate Buy” and a consensus target price of $43.39.
Read Our Latest Stock Report on Genmab A/S
Genmab A/S Trading Up 1.5%
Shares of Genmab A/S stock opened at $39.07 on Wednesday. Genmab A/S has a fifty-two week low of $23.62 and a fifty-two week high of $40.17. The business’s fifty day moving average is $34.68 and its two-hundred day moving average is $29.94. The company has a quick ratio of 2.44, a current ratio of 2.46 and a debt-to-equity ratio of 0.81. The firm has a market cap of $24.38 billion, a PE ratio of 27.70, a P/E/G ratio of 1.80 and a beta of 0.81.
Genmab A/S (NASDAQ:GMAB – Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported $0.54 earnings per share for the quarter, beating the consensus estimate of $0.37 by $0.17. The firm had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.12 billion. Genmab A/S had a net margin of 19.08% and a return on equity of 14.89%.
Institutional Trading of Genmab A/S
Several large investors have recently added to or reduced their stakes in the stock. WINTON GROUP Ltd raised its position in Genmab A/S by 158.9% in the second quarter. WINTON GROUP Ltd now owns 40,900 shares of the company’s stock valued at $1,124,000 after purchasing an additional 25,100 shares during the period. Diversify Wealth Management LLC acquired a new position in shares of Genmab A/S during the first quarter worth about $1,216,000. SummitTX Capital L.P. acquired a new position in shares of Genmab A/S during the first quarter worth about $2,263,000. Legacy Wealth Asset Management LLC boosted its position in shares of Genmab A/S by 164.1% in the second quarter. Legacy Wealth Asset Management LLC now owns 102,164 shares of the company’s stock worth $2,806,000 after buying an additional 63,484 shares during the period. Finally, Y Intercept Hong Kong Ltd purchased a new stake in shares of Genmab A/S in the first quarter worth about $1,198,000. 7.07% of the stock is currently owned by institutional investors and hedge funds.
Genmab A/S Company Profile
Genmab A/S is a biotechnology company headquartered in Copenhagen, Denmark, focused on discovering and developing differentiated antibody-based medicines for the treatment of cancer and other serious diseases. The company uses proprietary antibody technologies, including DuoBody and HexaBody, to create therapies designed to engage the immune system or target specific disease-related proteins.
Genmab’s marketed and partnered products include DARZALEX (daratumumab) for multiple myeloma, developed with Johnson & Johnson; EPKINLY (epcoritamab) for certain types of B-cell lymphoma, developed with AbbVie; and Tivdak (tisotumab vedotin) for cervical cancer, developed with Seagen.
Featured Articles
- Five stocks we like better than Genmab A/S
- Aurora Rejects Curaleaf’s Higher Bid, But the Takeover Fight Isn’t Over
- Centrus Energy Is Building a Nuclear Fuel Powerhouse—Why Is Its Stock Struggling?
- Halliburton Gains Traction: Multiyear Upcycle Ahead
- Meta Platforms’ AI Comeback Faces an Earnings Test—And a $10 Billion Charge
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.
